The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) provided a close look at two new antibiotics, highlighted the next generation of HIV therapies, and showed one way to sort through bacterial genomes quickly for key genes.

Investors last week got as close a chance as they may get at a head-to-head analysis of Phase III data on compounds being developed by Cubist Pharmaceuticals Inc. and InterMune Pharmaceuticals Inc. to treat complicated skin and soft tissue infections (cSSTs).